Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 18 Carcinoma, Non-Small-Cell Lung 14 Breast Neoplasms 14 Lung Neoplasms 12 Head and Neck Neoplasms 10 Rectal Neoplasms 8 Prostatic Neoplasms 7 Mouth Neoplasms 5 Glioblastoma 5 Esophageal Neoplasms 5 Colonic Neoplasms 5 Central Nervous System Neoplasms 5 Pancreatic Neoplasms 4 Oropharyngeal Neoplasms 4 Neoplasm Metastasis 4 Hypopharyngeal Neoplasms 4 Gliosarcoma 4 Carcinoma 4 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Ovarian Neoplasms 3 Neuroblastoma 3 Neoplasms 3 Laryngeal Neoplasms 3 Brain Neoplasms 3 Uterine Cervical Dysplasia 2 Turcot syndrome 2 Tongue Neoplasms 2 Salivary Gland Neoplasms 2 Recurrence 2

Interventions

Sirolimus 4 nintedanib 1 Sugars 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphangioleiomyomatosis × Celecoxib × Clear all

NCT02484664 2022-01-20

COLA

Brigham and Women's Hospital

Phase 2 Completed

12 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡